Quinten Health
Paris-based AI and data science firm that builds proprietary machine-learning models — including AliBERT, Q-Finder, and disease/care virtual twins — to generate real-world evidence, optimise clinical trials, and support regulatory and HTA submissions for pharmaceutical, biotech, and research clients.
- Company typePrivate
- Founded2021
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
Quinten Health firmographics
Firmographics- Name
- Quinten Health
- Legal name
- Quinten Health
- Website
- https://quinten-health.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Paris-based AI and data science firm that builds proprietary machine-learning models — including AliBERT, Q-Finder, and disease/care virtual twins — to generate real-world evidence, optimise clinical trials, and support regulatory and HTA submissions for pharmaceutical, biotech, and research clients.
- Ownership category
- akta.pro rank
Quinten Health industry classification
Industry- Product category
- Healthcare AI Data Science Services
- NAICS
- Health Care and Social Assistance (62), Marketing Research and Public Opinion Polling (54191), Computer Systems Design and Related Services (54151)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), Services-Management Consulting Services (8742), Services-Health Services (8000)
- akta.pro primary industry
- Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)
- akta.pro secondary industries
- Real-World Evidence (RWE) & HEOR for Development (HLAIALAI), Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
Keywords
Where Quinten Health is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Quinten Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Consulting & Data Science Services: B2B professional services providing AI-powered data science consulting to pharmaceutical companies, healthcare providers, research institutions, and regulatory agencies. Projects include disease modeling, RWE generation, clinical trial optimization, market access evidence, and regulatory submissions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Quinten Health product offering
Product offeringCore offering
Quinten Health is a healthcare data science and AI consulting firm that builds disease and care models, virtual twins, real-world evidence workflows, and French-biomedical NLP tools for pharmaceutical companies, healthcare providers, research institutions, and HTA/regulatory agencies. Its commercial deliverables center on four solution lines (Clinical & Medical, Access & Regulatory, Data & Digital, Corporate Development) supported by proprietary algorithms (Q-Finder, Qluster, AliBERT, SLR automation) and consortium platforms (AIOLOS, More-EUROPA).
Product overview
Quinten Health is an AI and data science company serving the life sciences industry with a portfolio of specialized solutions built around its Evidence Operating System framework. The core offering combines disease and care modeling with virtual twin simulation capabilities to support pharmaceutical R&D, regulatory submissions, and market access decisions. Key products include Q-Finder (subgroup discovery algorithm), Qluster (clustering method), and AliBERT (French biomedical language model). The company offers AI-powered tools for systematic literature reviews, RWD fit-for-use assessment, and registry evaluation, developed through collaborative EU projects (AIOLOS, More-EUROPA). Solutions target clinical, access, regulatory, and digital transformation teams across pharmaceutical companies, healthcare providers, and research institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical & Medical Solutions Consulting and AI-driven evidence generation service for clinical and medical teams in pharmaceutical and biotech companies, advancing clinical decision-making through explainable AI and real-world data, including disease progression modeling, RCT extrapolation, and synthetic control arms.
- Access & Regulatory Solutions Consulting and evidence-generation service for market access and regulatory affairs teams, reinforcing submission strategies through real-world evidence-powered positioning simulation and market access evidence generation.
- Data & Digital Solutions Consulting and AI engineering service for data and digital transformation teams within healthcare organizations, unlocking health data through medical text intelligence, NLP-based literature review, patient testimonials analysis, and cohort construction.
- Corporate Development Solutions Consulting and analytics service for corporate development and investment teams, supporting faster, better-informed investment and growth decisions through therapeutic-area potential evaluation and evidence-backed strategic planning.
- AI-Powered Systematic Literature Review (SLR) Tool Semi-automated AI screening tool using LLMs to accelerate title/abstract screening for systematic literature reviews, reducing manual workload by 46-91% while maintaining over 96% recall. Integrates with PubMed, Semantic Scholar, and Google Scholar, and targets evidence synthesis teams in pharma and research organizations.
- Real-World Digital Twins / Virtual Twin Platform Reference virtual twin generators that leverage AI/ML, predictive modeling, and pharmaco-epidemiology to simulate patient cohorts, project long-term real-world outcomes, emulate trials, and forecast medical and economic value for drugs in development. Announced at DIA Europe 2023.
- Disease Modeling Platform AI-powered disease modeling platform using patient disease progression, treatment trajectories, and care pathways to support development decisions in rare diseases, pediatrics, and constrained trial settings. Development funded by a €14 million round in September 2022.
- Regulatory-Grade Chronic Disease Cohort Simulator Regulatory-grade chronic disease cohort simulator built from the CONSTANCES cohort linked to the French SNDS claims database, combining statistical modeling, machine learning, causal inference, and health-economic methods to support HTA and regulatory submissions.
- AIOLOS Epidemic Monitoring Platform AI-powered web-based platform for outbreak detection and response, employing integrative modeling from diverse data sources to identify and track viral epidemics, with a focus on COVID-19 in France and Germany. Developed as part of the EU Horizon Europe-funded AIOLOS consortium.
- Registry Fit-for-Use Assessment Tool AI-powered tool developed under the More-EUROPA consortium to identify, select, and assess fit-for-purpose registries and data elements for drug development and evaluation, supporting regulators, HTA bodies, and researchers.
- AI-Powered RWD Fit-for-Use Assessment Tool AI tool to support the identification and selection of fit-for-use Real-World Data sources for evidence generation, enabling evaluation of data quality and suitability for regulatory and HTA purposes.
Quantifiable outcome
- Manual abstract screening reduced by 46% to 91% using AI-powered SLR tool, while capturing over 96% of articles identified by human experts
- +4 more outcomes
Companies that use Quinten Health
Customer profileNamed customers11 records
Segments7 records
Ideal customer profiles3 records
Quinten Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature16 records
Quinten Health partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, flagship and core.
- PhastarminorFollowing Billy Amzal's appointment as Head of Strategic Consulting at Phastar (from his former role as CEO of Quinten Health), Phastar and Quinten Health will continue collaborating on strategic initiatives. Billy Amzal brought over 25 years of experience in biotech, pharma, health agencies, and consulting.
- AI for Health Summit (Station F)minorQuinten Health participated at the AI for Health Summit 2023 at Station F in Paris, an event co-funded by Artefact and Johnson & Johnson that brings together healthcare and AI ecosystem players. The company had exhibition booth presence to showcase its expertise.
- Critical Path Institute (C-Path)flagshipQuinten Health and C-Path partnered to jointly design and advance regulatory-grade disease and care simulation for reducing risks in value-based trial designs and real-world prospective studies. The partnership combines Quinten Health's predictive disease and care modeling technologies with C-Path's expertise in Model-Informed Drug Development (MIDD) to de-risk and accelerate drug development by reducing uncertainty from disease heterogeneity, progression, and outcomes in real-life settings.
- More-EUROPA ConsortiumcoreQuinten Health participates in two work packages within the More-EUROPA consortium: (1) assessing the level of evidence and uncertainty for using registry data for pre-licensing exploratory objectives, and (2) leading the design of an AI automated tool to identify, select, and assess fit-for-purpose registries and data elements. The project aims to improve registry-based evidence for regulatory and HTA decision-making in Europe.
- Bpifrance & Business FranceminorQuinten Health was selected by Bpifrance and Business France to participate in the first 'Life Sciences in the Nordic Countries' mission, providing a business development program to accelerate development in the Nordic market (Denmark and Sweden). Part of the Nordic Health mission at Nordic Life Science Days 2023 in Copenhagen.
- UnicancerflagshipQuinten Health partnered with Unicancer to develop a real-world patient simulator in lung cancer. This collaboration leverages Quinten Health's AI and modeling expertise with Unicancer's French cancer center network data to create a virtual patient simulator for oncology clinical development and care optimization. Oncology is identified as one of Quinten Health's primary therapeutic areas and aligns with the Medicon Valley Nordic cluster's excellence in oncology.
- AIOLOS ConsortiumcoreThe AIOLOS project (Artificial Intelligence Tools for Outbreak Detection and Response) is a transnational platform for surveillance, monitoring, and decision support. Quinten Health contributes data preparation, AI, and healthcare expertise to build an AI monitoring tool to track viral epidemics (with focus on COVID-19 in France and Germany). The project received EU Horizon Europe funding.
- DIA EuropeminorQuinten Health participated as a featured speaker and session animator at DIA Europe 2023 in Basel, Switzerland. The company led a live session on 'Faster and smarter clinical development using disease and care simulation' with industry and regulatory leaders including Novartis and C-Path Institute.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Quinten Health competitors and assessment
Company assessmentDirect peers
- Owkin: Paris- and New York-based AI-for-health company using real-world data and federated learning to support pharma R&D and clinical development. Highly comparable to Quinten Health in disease modeling focus, RWE generation, and European biopharma customer base.
- Unlearn.AI: AI company building digital twins / synthetic control arms for clinical trial optimization. Direct overlap with Quinten Health's Real-World Digital Twins offering and regulatory-grade simulation capabilities for pharma R&D.
- CytoReason: Israel-based AI company building computational disease models for pharmaceutical drug discovery and development. Direct overlap with Quinten Health's Disease & Care Modeling products and pharma commercial model.
- GNS Healthcare: Causal AI platform for precision medicine and real-world evidence generation in oncology and other therapeutic areas. Comparable to Quinten Health in causal inference, individual treatment effect estimation, and pharma R&D use cases.
- Aetion: US-based real-world evidence analytics platform used by pharma, regulators, and HTA bodies for treatment effectiveness and value assessment. Comparable in RWE analytics and regulatory evidence use cases (also a named customer reference for Quinten Health).
- Phastar: Global CRO focused on biostatistics, data science, and strategic consulting for pharma and biotech. Direct overlap with Quinten Health's RWE and biostatistics consulting, and now a strategic partner following Billy Amzal's transition.
Broad incumbents
- Certara: Largest pure-play model-informed drug development (MIDD) and biosimulation company globally. Overlaps with Quinten Health's virtual twin, regulatory-grade modeling, and Bayesian borrowing offerings; Billy Amzal previously served as SVP at Certara.
- IQVIA: World's largest CRO with extensive real-world evidence, HEOR, and AI-driven analytics capabilities. Broad competitor across RWE, market access, and clinical trial optimization where Quinten Health operates.
- Flatiron Health: Roche subsidiary providing real-world evidence from oncology-specific EHR data for clinical research and regulatory submissions. Strong overlap with Quinten Health's oncology focus and RWE for pharma/biotech customers.
- Evidera (PPD / Thermo Fisher): Large HEOR, RWE, and market access consulting business within PPD/Thermo Fisher. Directly comparable in HEOR, market access evidence, and HTA submission support services that Quinten Health provides.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Quinten Health social profiles
Digital presenceQuinten Health compliance and trust
Trust signalCompliance1 record
Quinten Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quinten Health leadership team
Management profileNumber of profiles
Profiles7 records
Quinten Health funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quinten Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quinten Health
What does Quinten Health do?
Quinten Health is a healthcare data science and AI consulting firm that builds disease and care models, virtual twins, real-world evidence workflows, and French-biomedical NLP tools for pharmaceutical companies, healthcare providers, research institutions, and HTA/regulatory agencies. Its commercial deliverables center on four solution lines (Clinical & Medical, Access & Regulatory, Data & Digital, Corporate Development) supported by proprietary algorithms (Q-Finder, Qluster, AliBERT, SLR automation) and consortium platforms (AIOLOS, More-EUROPA).
Is Quinten Health a public or private company?
Quinten Health is a private company. It is classified as corporate owned and is currently operating.
When was Quinten Health founded?
Quinten Health was founded in 2021. It employs 11 to 50 people.
Where is Quinten Health based?
Quinten Health is headquartered in Paris, France, in the Europe region.
How does Quinten Health make money?
One revenue line is on record: consulting & Data Science Services.
Who are Quinten Health's main competitors?
Direct peers on record are Owkin, Unlearn.AI, CytoReason, GNS Healthcare, Aetion and Phastar. Broad incumbents are Certara, IQVIA, Flatiron Health and Evidera (PPD / Thermo Fisher).
Does Quinten Health have an API?
No public API is recorded for Quinten Health.
What industry is Quinten Health in?
Quinten Health's product category is Healthcare AI Data Science Services. Its primary akta.pro industry code is HLAGAAAK, Real-World Evidence (RWE), HEOR & Epidemiology CROs, with a secondary code of HLAIALAI, Real-World Evidence (RWE) & HEOR for Development. Its NAICS code is 62 and its SIC code is 8090.